- Home
- IRMD vs REPL Comparison
IRMD vs REPL Comparison
Compare IRMD & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- REPL
- Stock Information
- Founded
- IRMD 1992
- REPL 2015
- Country
- IRMD United States
- REPL United States
- Employees
- IRMD N/A
- REPL N/A
- Industry
- IRMD Medical/Dental Instruments
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- REPL Health Care
- Exchange
- IRMD Nasdaq
- REPL Nasdaq
- Market Cap
- IRMD 668.2M
- REPL 753.9M
- IPO Year
- IRMD 2014
- REPL 2018
- Fundamental
- Price
- IRMD $58.24
- REPL $9.27
- Analyst Decision
- IRMD Strong Buy
- REPL Strong Buy
- Analyst Count
- IRMD 1
- REPL 7
- Target Price
- IRMD $72.00
- REPL $20.83
- AVG Volume (30 Days)
- IRMD 48.5K
- REPL 1.3M
- Earning Date
- IRMD 07-31-2025
- REPL 08-07-2025
- Dividend Yield
- IRMD 1.18%
- REPL N/A
- EPS Growth
- IRMD 10.72
- REPL N/A
- EPS
- IRMD 1.55
- REPL N/A
- Revenue
- IRMD $75,154,639.00
- REPL N/A
- Revenue This Year
- IRMD $10.62
- REPL N/A
- Revenue Next Year
- IRMD $9.69
- REPL N/A
- P/E Ratio
- IRMD $37.23
- REPL N/A
- Revenue Growth
- IRMD 11.04
- REPL N/A
- 52 Week Low
- IRMD $42.11
- REPL $6.44
- 52 Week High
- IRMD $63.29
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- IRMD 55.66
- REPL 49.26
- Support Level
- IRMD $57.66
- REPL $9.50
- Resistance Level
- IRMD $59.91
- REPL $10.09
- Average True Range (ATR)
- IRMD 1.71
- REPL 0.60
- MACD
- IRMD -0.29
- REPL -0.06
- Stochastic Oscillator
- IRMD 44.82
- REPL 9.76
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.